ELDN RSI Chart
Last 7 days
13.9%
Last 30 days
19.2%
Last 90 days
33.0%
Trailing 12 Months
-2.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2017 | 136.0K | 0 | 0 | 0 |
2016 | 188.0K | 212.0K | 196.0K | 164.0K |
2015 | 168.0K | 170.0K | 172.0K | 174.0K |
2014 | 0 | 0 | 0 | 166.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 05, 2023 | bvf partners l p/il | bought | - | - | 1,978,930 | - |
Nov 23, 2022 | perrin steven | bought | 2,596 | 2.5969 | 1,000 | president |
Dec 20, 2021 | gros david-alexandre c | bought | 8,960 | 4.48 | 2,000 | chief executive officer |
Aug 17, 2021 | gros david-alexandre c | bought | 24,840 | 6.21 | 4,000 | chief executive officer |
Jun 11, 2021 | little paul sean | bought | 88,700 | 8.87 | 10,000 | chief financial officer |
Jun 09, 2021 | gros david-alexandre c | bought | 24,030 | 8.01 | 3,000 | chief executive officer |
Which funds bought or sold ELDN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 30, 2024 | JMAC ENTERPRISES LLC | unchanged | - | 15,090 | 119,564 | 0.02% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -5,000 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 3.1 | 327,660 | 1,251,750 | -% |
Feb 15, 2024 | MERCER GLOBAL ADVISORS INC /ADV | unchanged | - | 7,000 | 30,000 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 52.58 | 77,872 | 155,381 | -% |
Feb 14, 2024 | RMB Capital Management, LLC | sold off | -100 | -13,700 | - | -% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 21,204 | 21,204 | -% |
Feb 14, 2024 | Ensign Peak Advisors, Inc | unchanged | - | 190,491 | 797,402 | -% |
Feb 14, 2024 | TWO SIGMA ADVISERS, LP | sold off | -100 | -17,947 | - | -% |
Unveiling Eledon Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Eledon Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.1B | 6.8B | -8.06 | 7.03 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.0B | 2.0B | -57.25 | 9.49 | ||||
BMRN | 15.9B | 2.5B | 77.41 | 6.43 | ||||
INCY | 11.9B | 3.8B | 15.99 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.83 | 14.44 | ||||
BBIO | 5.2B | 107.9M | -9.5 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.69 | 12.99 | ||||
ARWR | 3.0B | 240.7M | -10.07 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.92 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.79 | 4.45 | ||||
NVAX | 659.2M | 983.7M | -1.21 | 0.67 | ||||
CRBP | 400.8M | 881.7K | -8.99 | 466.16 | ||||
INO | 280.7M | 4.9M | -2.08 | 57.68 | ||||
IBIO | 7.0M | 2.1M | -0.26 | 2.14 |
Eledon Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q2 | 2014Q1 |
Revenue | 13.0% | 26,000 | 23,000 | 38,000 | 49,000 | 54,000 | 55,000 | 54,000 | 25,000 | 40,000 | 37,000 | 34,000 | 45,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -7.3% | 89.00 | 96.00 | 107 | 82.00 | 93.00 | 150 | 155 | 161 | 171 | 177 | 184 | 192 | 197 | 193 | 11.00 | 14.00 | 11.00 | 15.00 | 18.00 | 13.00 | 17.00 |
Current Assets | -10.9% | 56.00 | 63.00 | 74.00 | 49.00 | 60.00 | 68.00 | 73.00 | 79.00 | 88.00 | 96.00 | 103 | 110 | 116 | 115 | 10.00 | 13.00 | 10.00 | 12.00 | 15.00 | 10.00 | 14.00 |
Cash Equivalents | 25.8% | 5.00 | 4.00 | 41.00 | 47.00 | 56.00 | 66.00 | 70.00 | 77.00 | 85.00 | 94.00 | 101 | 109 | 114 | 114 | 9.00 | 12.00 | 9.00 | 11.00 | 14.00 | 14.00 | 13.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | - | - | - | - | - | - | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 44.00 | - | - | - | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | 19.3% | 6.00 | 5.00 | 7.00 | 8.00 | 9.00 | 8.00 | 5.00 | 5.00 | 7.00 | 6.00 | 6.00 | 8.00 | 7.00 | 6.00 | 1.00 | 2.00 | 1.00 | 2.00 | 2.00 | 4.00 | 3.00 |
Current Liabilities | 34.4% | 4.00 | 3.00 | 5.00 | 5.00 | 6.00 | 6.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 2.00 | 6.00 | 1.00 | 2.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 |
Shareholder's Equity | -8.7% | 83.00 | 91.00 | 100 | 75.00 | 84.00 | 141 | 149 | 156 | 164 | 171 | 179 | 184 | 191 | 22.00 | 9.00 | 12.00 | 9.00 | 13.00 | 16.00 | 10.00 | 14.00 |
Retained Earnings | -4.1% | -243 | -233 | -223 | -213 | -202 | -144 | -134 | -124 | -114 | -106 | -96.30 | -88.89 | -80.39 | -74.49 | -68.34 | -65.76 | -57.58 | -53.44 | -50.54 | -46.45 | -41.57 |
Additional Paid-In Capital | 0.5% | 327 | 325 | 323 | 288 | 287 | 286 | 283 | 281 | 279 | 277 | 275 | 273 | 271 | 96.00 | 78.00 | 77.00 | 67.00 | 67.00 | 67.00 | 56.00 | 56.00 |
Shares Outstanding | 2.8% | 24.00 | 24.00 | 23.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 15.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | 26.00 | - | - | - | 34.00 | - | - | - | 113 | - | - | - | 7.00 | - | - | - | 10.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 25.5% | -9,131 | -12,251 | -8,221 | -9,924 | -9,480 | -4,571 | -6,217 | -8,156 | -9,208 | -7,093 | -7,446 | -5,166 | -9,433 | -561 | -3,021 | -2,197 | -2,023 | -2,889 | -4,922 | -4,023 | -3,353 |
Share Based Compensation | -1.4% | 1,710 | 1,734 | 1,720 | 1,381 | 1,474 | 2,185 | 2,308 | 2,186 | 2,053 | 2,043 | 2,034 | 1,774 | 1,659 | 878 | 197 | 437 | 243 | 227 | 627 | 211 | 741 |
Cashflow From Investing | 140.3% | 10,076 | -25,029 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | - | 1.00 | - | -450 | 9,164 | 95,226 | - | 5,191 | - | - | 9,569 | 107 | 1.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses | ||
Research and development | $ 30,312,000 | $ 27,080,000 |
General and administrative | 12,688,000 | 12,700,000 |
Goodwill impairment | 0 | 48,648,000 |
Total operating expenses | 43,000,000 | 88,428,000 |
Loss from operations | (43,000,000) | (88,428,000) |
Other income, net | 2,674,000 | 462,000 |
Loss before income taxes | (40,326,000) | (87,966,000) |
Income taxes | 0 | 0 |
Net loss and comprehensive loss | $ (40,326,000) | $ (87,966,000) |
Net loss per share, basic | $ (1.64) | $ (6.16) |
Net loss per share, diluted | $ (1.64) | $ (6.16) |
Weighted-average common shares outstanding, basic | 24,619,197 | 14,285,254 |
Weighted-average common shares outstanding, diluted | 24,619,197 | 14,285,254 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,612,000 | $ 56,409,000 |
Short-term investments | 46,490,000 | 0 |
Prepaid expenses and other current assets | 5,027,000 | 3,109,000 |
Total current assets | 56,129,000 | 59,518,000 |
Operating lease asset, net | 365,000 | 739,000 |
In-process research and development | 32,386,000 | 32,386,000 |
Other assets | 186,000 | 150,000 |
Total assets | 89,066,000 | 92,793,000 |
Current liabilities: | ||
Accounts payable | 967,000 | 2,200,000 |
Current operating lease liability | 383,000 | 363,000 |
Accrued expenses and other liabilities | 2,545,000 | 3,912,000 |
Total current liabilities | 3,895,000 | 6,475,000 |
Deferred tax liability | 1,752,000 | 1,752,000 |
Non-current operating lease liability | 0 | 383,000 |
Total liabilities | 5,647,000 | 8,610,000 |
Commitments and contingencies (Note 8) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2023 and 2022; 24,213,130 and 13,776,788 shares issued and outstanding at December 31, 2023 and 2022, respectively | 24,000 | 14,000 |
Additional paid-in capital | 326,586,000 | 287,034,000 |
Accumulated deficit | (243,191,000) | (202,865,000) |
Total stockholders’ equity | 83,419,000 | 84,183,000 |
Total liabilities and stockholders’ equity | 89,066,000 | 92,793,000 |
Series X1 Non-voting Convertible Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock, value | ||
Series X Non-voting Convertible Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock, value |